-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Guolong Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Awarded “Provincial Model Enterprise for Technological Innovation”
Category:
发布时间：2022-01-20
【概要描述】
Recently, the Hebei Provincial Department of Industry and Information Technology released the list of 2021 Hebei Provincial Model Enterprises for Technological Innovation. Shijiazhuang Sihua Pharmaceutical Group’s Hebei Guolong Pharmaceutical Co., Ltd. was recognized as a 2021 Hebei Provincial Model Enterprise for Technological Innovation.
Recently, the Hebei Provincial Department of Industry and Information Technology released the list of 2021 Hebei Provincial Model Enterprises for Technological Innovation. Shijiazhuang Sihua Pharmaceutical Group’s Hebei Guolong Pharmaceutical Co., Ltd. was recognized as a 2021 Hebei Provincial Model Enterprise for Technological Innovation.
As a wholly owned subsidiary of Shijiazhuang Sihua Pharmaceutical Group, Guolong Pharmaceutical has, in recent years, leveraged the Group’s robust overall strength and advanced management practices to vigorously implement a “API-plus-formulation” strategy. Anchored by industry–university–research–application collaboration, the company has aligned its development priorities with precision, product serialization, and distinctive specialty offerings, with a strong focus on building technological platforms and developing new products as the core of an enterprise-driven innovation system. It has continuously undertaken technological upgrades and steadily advanced improvements in management, technology, product quality, environmental protection, and safety. As a result, a number of innovative, specialty products in areas such as anti-infectives, volume-expanding agents, respiratory medications, psychotropic drugs, and novel therapeutics have been rapidly commercialized and industrialized, establishing a new, phased industrial development model characterized by “a batch of R&D projects, a batch of technology transfers, and a batch of pipeline assets.” Consequently, the company’s market share has increased markedly, providing substantial momentum for its transformation, upgrading, and pursuit of differentiated competitiveness. Guolong Pharmaceutical has successively been recognized as a High-Tech Enterprise, an A-level R&D institution among industrial enterprises in Hebei Province, and a “Specialized, Refined, Distinctive, and Innovative” SME in Hebei Province, thereby playing an increasingly prominent demonstration role in leading and driving technological innovation within the industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091